DE602007013618D1 - Antikörper gegen das humane cytomegalie-virus (hcmv) - Google Patents

Antikörper gegen das humane cytomegalie-virus (hcmv)

Info

Publication number
DE602007013618D1
DE602007013618D1 DE602007013618T DE602007013618T DE602007013618D1 DE 602007013618 D1 DE602007013618 D1 DE 602007013618D1 DE 602007013618 T DE602007013618 T DE 602007013618T DE 602007013618 T DE602007013618 T DE 602007013618T DE 602007013618 D1 DE602007013618 D1 DE 602007013618D1
Authority
DE
Germany
Prior art keywords
hcmv
cytomegalie
antibodies
virus
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007013618T
Other languages
English (en)
Inventor
Ada Funaro
Giorgio Gribaudo
Santo Landolfo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribovax Biotechnologies SA
Original Assignee
Ribovax Biotechnologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2006/069780 external-priority patent/WO2007068758A1/en
Application filed by Ribovax Biotechnologies SA filed Critical Ribovax Biotechnologies SA
Publication of DE602007013618D1 publication Critical patent/DE602007013618D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602007013618T 2006-12-15 2007-12-17 Antikörper gegen das humane cytomegalie-virus (hcmv) Active DE602007013618D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2006/069780 WO2007068758A1 (en) 2005-12-16 2006-12-15 Methods for obtaining immortalized antibody secreting cells
EP07110693 2007-06-20
PCT/EP2007/064094 WO2008071806A1 (en) 2006-12-15 2007-12-17 Antibodies against human cytomegalovirus (hcmv)

Publications (1)

Publication Number Publication Date
DE602007013618D1 true DE602007013618D1 (de) 2011-05-12

Family

ID=40935039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007013618T Active DE602007013618D1 (de) 2006-12-15 2007-12-17 Antikörper gegen das humane cytomegalie-virus (hcmv)

Country Status (18)

Country Link
US (1) US8153129B2 (de)
EP (1) EP2126049B1 (de)
JP (1) JP5351041B2 (de)
KR (1) KR20090114364A (de)
CN (1) CN101627115B (de)
AT (1) ATE503769T1 (de)
AU (1) AU2007331463B2 (de)
BR (1) BRPI0720464A2 (de)
CA (1) CA2672703C (de)
DE (1) DE602007013618D1 (de)
DK (1) DK2126049T3 (de)
EA (1) EA018701B1 (de)
ES (1) ES2363992T3 (de)
IL (1) IL199366A (de)
NO (1) NO20092671L (de)
PL (1) PL2126049T3 (de)
PT (1) PT2126049E (de)
WO (1) WO2008071806A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
EP2190876A1 (de) * 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Antikörper gegen das humane cytomegalie-virus (hcmv)
SG10201608381SA (en) 2008-07-16 2016-11-29 Inst Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
CA2738176C (en) * 2008-09-23 2012-01-10 Hema-Quebec Method for polyclonal immunoglobulin g production by human b cells
BR112012015523A2 (pt) 2009-12-23 2017-04-18 4-Antibody Ag membros de ligação do citomegalovirus humano, composição contendo os mesmos, método de tratamento, moléculas de anticorpo, método de produção, molecular de ácido nucléico, célula hospedeira, e, método de neutralização do hcmv.
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
US9139659B2 (en) 2012-03-28 2015-09-22 Genentech, Inc. Idiotypic antibodies and uses thereof
KR101581158B1 (ko) 2014-03-26 2015-12-30 울산대학교 산학협력단 거대세포바이러스 실제 감염 여부를 진단하기 위한 거대세포바이러스의 감염 해석 모델
SG11201609639VA (en) * 2014-05-19 2016-12-29 Hoffmann La Roche Method for production of polypeptides
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2021110126A1 (zh) 2019-12-04 2021-06-10 珠海泰诺麦博生物技术有限公司 抗人巨细胞病毒抗体及其用途
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1445243A (zh) * 2002-12-13 2003-10-01 中国疾病控制中心病毒病预防控制所 抗人巨细胞病毒人源中和性基因工程Fab抗体
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders

Also Published As

Publication number Publication date
DK2126049T3 (da) 2011-07-18
AU2007331463A1 (en) 2008-06-19
PT2126049E (pt) 2011-07-04
US8153129B2 (en) 2012-04-10
PL2126049T3 (pl) 2011-09-30
CA2672703C (en) 2016-11-22
EP2126049B1 (de) 2011-03-30
NO20092671L (no) 2009-09-03
JP2010512736A (ja) 2010-04-30
JP5351041B2 (ja) 2013-11-27
ATE503769T1 (de) 2011-04-15
CN101627115B (zh) 2013-05-29
WO2008071806A1 (en) 2008-06-19
KR20090114364A (ko) 2009-11-03
IL199366A (en) 2015-03-31
US20100040602A1 (en) 2010-02-18
BRPI0720464A2 (pt) 2014-01-14
EA018701B1 (ru) 2013-10-30
CA2672703A1 (en) 2008-06-19
AU2007331463B2 (en) 2014-03-27
CN101627115A (zh) 2010-01-13
EP2126049A1 (de) 2009-12-02
ES2363992T3 (es) 2011-08-22
EA200970586A1 (ru) 2009-12-30

Similar Documents

Publication Publication Date Title
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
EA201000424A1 (ru) Антитела к il-23
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EP2016173A4 (de) Verfahren und zusammensetzungen zur behandlung menschlicher immundefekt-virusinfektionen mit konjugierten antikörpern oder antikörperfragmenten
UA109633C2 (uk) Антитіло людини проти тканинного фактора
TR201900764T4 (tr) LAG-3 ve terapötik antikorlar içeren bileşimler ve bunların kanser tedavisinde kullanımı.
WO2012021786A3 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201070794A1 (ru) Рекомбинантные антигены rsv
CY1114577T1 (el) Αποτροπη και θεραπεια υπο-κλινικης pcvd
EA200901490A1 (ru) Химические соединения
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
ATE503770T1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201000735A1 (ru) Композиции многотипных пептидов hpv и способы лечения или предотвращения папилломавирусной инфекции у человека
EA201001212A1 (ru) Лечение микробных инфекций
EA201170353A1 (ru) Антитела против гепатита с и их применение
TR201907261T4 (tr) DKK-1 antikorları.
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич